SCHEMBL25434669

SCHEMBL25434669

C[C@@H]1CN(S(=O)(=O)c2cn(C)cn2)CC[C@@H]1Nc1ncc(C(F)(F)F)c(-c2cnc(C(C)(C)O)s2)n1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 14/20 0.52
▸ CDK2 P24941 14/20 0.52
▸ CCND1 P24385 11/20 0.52
▸ CDK6 Q00534 11/20 0.52
▸ CDK4 P11802 9/20 0.52
▸ CCND3 P30281 9/20 0.52
▸ CDK1 P06493 9/20 0.52
▸ CCNB1 P14635 9/20 0.52
▸ CCNT1 O60563 4/20 0.52
▸ CDK7 P50613 4/20 0.52
▸ CDK9 P50750 4/20 0.52
▸ CCNH P51946 4/20 0.52
▸ MNAT1 P51948 4/20 0.52
▸ SLC6A9 P48067 2/20 0.38
▸ POLB P06746 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30537231 1.00 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL25434836 0.90 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30537171 0.90 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL25434423 0.88 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30537181 0.88 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30537257 0.88 CCNE1 (0.47) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL30906838 0.88 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL27213114 0.88 CCNE1 (0.52) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL27213293 0.87 CCNE1 (0.54) CCNE1CDK2CCND1CDK6CDK4
SCHEMBL27213121 0.86 CCNE1 (0.48) CCNE1CDK2CCND1CDK6CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US claimed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 — — WO claimed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US disclosed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US disclosed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 — — US disclosed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CCNE1 36/4885CDK2 4/4885CCND1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback